SIGHT fundamentals
An in-depth look to GENSIGHT BIOLOGICS operating, investing, and financing activities
SIGHT free cash flow for H2 24 is -5.81 M EUR. For 2024, SIGHT free cash flow was -13.22 M EUR and operating cash flow was -13.21 M EUR.
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
TTM